Axicabtagene Ciloleucel and Increasing Accessibility to CAR T-Cell Therapy With Frederick Locke, MD

While the current standard of care for relapsed/refractory large B-cell lymphoma is high-dose therapy with autologous stem cell rescue, many patients do not respond to or cannot tolerate high-dose therapy. As a result, outcomes for second-line treatment remain poor. At the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, Dr. Frederick Locke of Moffitt Cancer Center presented the primary results of ZUMA-7, a phase 3 clinical trial investigating...

Continue reading

Axicabtagene Ciloleucel Approved for Second-Line Treatment of Large B-Cell Lymphoma

The FDA has approved axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for treatment of adult patients with large B-cell lymphoma (LBCL). Axicabtagene ciloleucel, also known as axi-cel, is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. It is indicated as a second-line treatment for patients who have already undergone first-line chemoimmunotherapy with no response or who have experienced relapse within 12 months of first-line chemoimmunotherapy. It is noted that axic...

Continue reading

Axicabtagene Ciloleucel for Follicular Lymphoma: Julio Chavez, MD

Recently, the FDA approved axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. The approval was based on results from ZUMA-5, a phase 2 trial in which axicabtagene ciloleucel demonstrated a high rate of efficacy. In this interview, one of the study investigators, Julio Chavez, MD, of the Moff...

Continue reading

FDA Approves Axicabtagene Ciloleucel for Relapsed/Refractory Follicular Lymphoma

The FDA has granted accelerated approval to axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. An indolent form of non-Hodgkin lymphoma (NHL) that is not generally curable, FL is considered a chronic disease. Therefore, people living with FL often require second-line therapies after their di...

Continue reading

CAR T-Cell Therapy: New Treatment for Large B-Cell Lymphoma

Large B-cell lymphoma is an extremely destructive, invasive subtype of non-Hodgkin lymphoma. Often, patients with this malignancy have undergone several treatments that have not worked. New therapeutic approaches are necessary for relapsed/refractory disease. A breakthrough personalized treatment, CAR T-cell therapy may be an option for patients with relapsed/refractory large B-cell lymphoma. Patients undergo a process called leukapheresis, in which a patient's blood is collected and put through...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.